5-methyl-6-[1-(2,2,2-trichloroethoxycarbonyl)-3-methyl-1,4-dihydro-4-pyridinyl]-2H-1,4-thiazin-3(4H)-one | 98320-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-methyl-6-[1-(2,2,2-trichloroethoxycarbonyl)-3-methyl-1,4-dihydro-4-pyridinyl]-2H-1,4-thiazin-3(4H)-one
• 英文别名: 2,2,2-trichloroethyl 3-methyl-4-(3-methyl-5-oxo-4H-1,4-thiazin-2-yl)-4H-pyridine-1-carboxylate
• CAS: 98320-17-3
• 化学式: C₁₄H₁₅Cl₃N₂O₃S
• 分子量: 397.71
• InChiKey: QUFNHSARBAUNSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  83.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-methyl-6-[1-(2,2,2-trichloroethoxycarbonyl)-3-methyl-1,4-dihydro-4-pyridinyl]-2H-1,4-thiazin-3(4H)-one 在 sulfur 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以85%的产率得到5-methyl-6-(3-methyl-4-pyridinyl)-2H-1,4-thiazin-3(4H)-one
  参考文献：
  名称：

  Studies on bi-heterocyclic compounds. I. 6-Substituted dihydro-1,4-thiazinones.

  摘要：

  5-甲基-2H-1,4-噻嗪-3(4H)-酮(4)与各种N-酰基吡啶盐(7a-g)反应得到(N-酰基二氢吡啶基)噻嗪酮(5a-g)，将其氧化得到一类新的吡啶基噻嗪酮(6a-g)。这些反应被应用于其他含氮芳基噻嗪酮的合成。其中一些含氮芳基噻嗪酮，特别是6-(4-吡啶基)噻嗪酮(6a, 14a和14b)，显示出了对豚鼠左心房有正性肌力作用和较小的变时效应。

  DOI：

  10.1248/cpb.35.2243
• 作为产物：
  描述：

  5-methyl-2H-1,4-thiazin-3(4H)-one 生成 5-methyl-6-[1-(2,2,2-trichloroethoxycarbonyl)-3-methyl-1,4-dihydro-4-pyridinyl]-2H-1,4-thiazin-3(4H)-one
  参考文献：
  名称：

  TAKASE, MUNEAKI;YOSHIOKA, KIMITOMO;YAMAZAKI, HIROAKI

  摘要：

  DOI：

文献信息

• 1,4-thiazine derivative, and cardiotonic agent comprising it as
  申请人：Zenyaku Kogyo Kabushiki Kaisha

  公开号：US04800201A1

  公开（公告）日：1989-01-24

  A novel 1,4-thiazine derivative represented by the formula I, a pharmaceutically acceptable acid addition salt thereof, a process for preparation thereof and a cardiotonic agent comprising it as an effective component; ##STR1## wherein R.sub.1 and R.sub.2 represent respectively hydrogen atom, lower alkyl group, lower alkoxy group, amino group, lower alkyl-amino group, aryl-amino group, hydroxy group, aryl group or 5- or 6-membered heterocyclic residue; R.sub.3 and R.sub.4 represent hydrogen atom or lower alkyl group; and R.sub.5 represents N-containing heterocyclic residue and is not pyridinyl group when R.sub.1 and R.sub.2 represent hydrogen atom and R.sub.3 and R.sub.4 represent hydrogen atom or lower alkyl group.

  一种由式I代表的新型1,4-噻嗪衍生物，其药学上可接受的酸盐，其制备方法以及作为有效成分的强心药剂；其中R.sub.1和R.sub.2分别代表氢原子，较低的烷基基团，较低的烷氧基团，氨基，较低的烷基氨基团，芳基氨基团，羟基，芳基或5-或6-成员杂环残基；R.sub.3和R.sub.4代表氢原子或较低的烷基基团；R.sub.5代表含氮杂环残基，当R.sub.1和R.sub.2代表氢原子且R.sub.3和R.sub.4代表氢原子或较低的烷基基团时，R.sub.5不代表吡啶基。
• 1,4-Thiazine derivatives
  申请人：Zenyaku Kogyo Kabushiki Kaisha

  公开号：US04565813A1

  公开（公告）日：1986-01-21

  Disclosed is a novel 1,4-thiazine derivatives represented by the following general formula I and a pharmaceutically acceptable acid addition salt thereof: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 respectively represent a hydrogen atom or a lower alkyl group. Also disclosed are processes for preparation of a novel thiazine derivative represented by the general formula I, which comprise reacting a compound of the general formula III with a compound of the general formula A-X' in a compound containing a pyridinyl group as a solvent to obtain a compound of the general formula II: ##STR2## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined above, A represents a group ##STR3## in which X represents a halogen atom and n is a number of 1 to 3, and X' represents a halogen atom which may be the same as or different from X, and reacting the compound of the general formula II with sulfur at elevated temperature or stirring the compound of the general formula II in a solution system comprising zinc and a carboxylic acid. Further disclosed is a cardiotonic agent comprising a pharmaceutically acceptable excipient and, as the active component thereof, an effective amount of the novel 1,4-thiazine derivative having the general formula I.

  本发明公开了一种由以下一般式I表示的新颖的1,4-噻嗪衍生物及其药学上可接受的酸盐：其中R.sub.1、R.sub.2和R.sub.3分别表示氢原子或较低的烷基基团。还公开了制备由一般式I表示的新颖噻嗪衍生物的方法，包括将一般式III的化合物与一般式A-X'的化合物在含有吡啶基团的化合物中作为溶剂中反应，以获得一般式II的化合物：其中R.sub.1、R.sub.2和R.sub.3如上所定义，A代表一个基团##在其中X代表卤原子，n为1至3的数，X'代表可能与X相同或不同的卤原子，并且将一般式II的化合物与硫在高温下反应或将一般式II的化合物在包含锌和羧酸的溶液体系中搅拌。还公开了一种包括药学上可接受的赋形剂和作为其活性成分的一种有效量的具有一般式I的新颖1,4-噻嗪衍生物的强心剂。
• Novel 1,4-thiazine derivative
  申请人：ZENYAKU KOGYO KABUSHIKI KAISHA

  公开号：EP0138058A1

  公开（公告）日：1985-04-24

  Disclosed is a novel 1,4-thiazine derivative represented by the following general formula I and a pharmaceutically acceptable acid addition salt thereof: wherein R1, R2 and R3 respectively represent a hydrogen atom or a lower alkyl group. Also disclosed are processes for preparation of a novel thiazine derivative represented by the general formula I, which comprise reacting a compound of the general formula III with a compound of the general formula A-X' in a compound containing a pyridinyl group as a solvent to obtain a compound of the general formula II: wherein R,, R2 and R3 are as defined above, A represents a group in which X represents a halogen atom and n is a number of 1 to 3, and X' represents a halogen atom which may be the same as or different from X, and reacting the compound of the general formula II with sulfur at elevated temperature or stirring the compound of the general formula II in a solution system comprising zinc and a carboxylic acid. Further disclosed is a cardiotonic agent comprising a pharmaceutically acceptable excipient and, as the active component thereof, an effective amount of the novel 1,4-thiazine derivative having the general formula I.

  本发明公开了由以下通式 I 代表的新型 1,4-噻嗪衍生物及其药学上可接受的酸加成盐： 其中 R1、R2 和 R3 分别代表氢原子或低级烷基。还公开了制备通式 I 所代表的新型噻嗪衍生物的工艺，该工艺包括在含有吡啶基的化合物中作为溶剂使通式 III 的化合物与通式 A-X' 的化合物反应，得到通式 II 的化合物： 其中 R、R2 和 R3 如上定义，A 代表一个基团 其中 X 代表卤原子，n 为 1 至 3 的数字，X'代表卤原子，可以与 X 相同或不同，将通式 II 的化合物与硫在高温下反应，或将通式 II 的化合物在由锌和羧酸组成的溶液体系中搅拌。进一步公开的是一种强心剂，包括一种药学上可接受的赋形剂，以及作为其活性成分的有效量的具有通式 I 的新型 1,4-噻嗪衍生物。
• 1,4-THIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND CARDIOTONICS CONTAINING THE SAME
  申请人：ZENYAKU KOGYO KABUSHIKI KAISHA

  公开号：EP0233287A1

  公开（公告）日：1987-08-26

  Novel 1,4-thiazine derivatives represented by general formula (I) wherein R1 and R2 each represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, an amino group, a lower alkylamino group, an arylamino group, a hydroxy group, an aryl group, a 5- or 6-membered heterocyclic ring residue, R3 and R4 each represents a hydrogen atom or a lower alkyl group, R5 represents a nitrogen-containing ring residue (provided that, when R, and R2 represent a hydrogen atom and R3 and R4 each represents a hydrogen atom or a lower alkyl group, R5 does not represent a pyridinyl group) and pharmacologically acceptable acid addition salts thereof, process for their preparation, and cardiotonics containing them as effective ingredients.

  通式(I)代表的新型1，4-噻嗪衍生物 其中R1和R2各自代表氢原子、低级烷基、低级烷氧基、氨基、低级烷基氨基、芳基氨基、羟基、芳基、5或6元杂环残基，R3和R4各自代表氢原子或低级烷基、R5 代表含氮环残基（条件是，当 R 和 R2 代表氢原子，R3 和 R4 各自代表氢原子或低级烷基时，R5 不代表吡啶基）及其药理学上可接受的酸加成盐、其制备工艺和含有它们作为有效成分的强心剂。
• YAMAZAKI HIROAKI; HARADA HIDENORI; MATSUZAKI KENICHI; YOSHIOKA KIMITOMO; +, CHEM. AND PHARM. BULL., 35,(1987) N 6, 2243-2253
  作者：YAMAZAKI HIROAKI、 HARADA HIDENORI、 MATSUZAKI KENICHI、 YOSHIOKA KIMITOMO、 +

  DOI：——

  日期：——